TrialRMD open2025

Upadacitinib as monotherapy in patients with rheumatoid arthritis and prior inadequate response to methotrexate: results at 260 weeks from the SELECT-MONOTHERAPY randomised study.

Josef S Smolen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.